NewAmsterdam Pharma Company NAMS Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's stock issuance proceeds?
- NewAmsterdam Pharma Company (NAMS) reported stock issuance proceeds of $10.41M in Q1 2026.
- How has NewAmsterdam Pharma Company's stock issuance proceeds changed year-over-year?
- NewAmsterdam Pharma Company's stock issuance proceeds increased by 31.5% year-over-year, from $7.92M to $10.41M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.